Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1987 1
1988 1
1991 1
1992 2
1993 3
1994 8
1995 3
1996 4
1997 5
1998 8
1999 5
2000 8
2001 8
2002 10
2003 1
2004 5
2005 11
2006 10
2007 9
2008 6
2009 2
2010 4
2011 7
2012 8
2013 7
2014 11
2015 4
2016 7
2017 3
2018 10
2019 16
2020 12
2021 10
2022 8
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Prostate Adenocarcinoma with Neuroendocrine Differentiation"
Page 1
Neuroendocrine neoplasms of the appendix, colon and rectum.
Volante M, Grillo F, Massa F, Maletta F, Mastracci L, Campora M, Ferro J, Vanoli A, Papotti M. Volante M, et al. Pathologica. 2021 Feb;113(1):19-27. doi: 10.32074/1591-951X-230. Pathologica. 2021. PMID: 33686307 Free PMC article. Review.
Neuroendocrine neoplasms of the appendix, colon and rectum are classified according to the most recent WHO classification as neuroendocrine tumors (NET), neuroendocrine carcinomas (NEC) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNE …
Neuroendocrine neoplasms of the appendix, colon and rectum are classified according to the most recent WHO classification as neuro …
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, Chen X, Jiang XS, McCall SJ, Inman BA, Huang J. Cheng Q, et al. Eur Urol. 2022 May;81(5):446-455. doi: 10.1016/j.eururo.2021.12.039. Epub 2022 Jan 17. Eur Urol. 2022. PMID: 35058087 Free PMC article.
BACKGROUND: Hormonal therapy targeting the androgen receptor inhibits prostate cancer (PCa), but the tumor eventually recurs as castration-resistant prostate cancer (CRPC). ...DESIGN, SETTING, AND PARTICIPANTS: We isolated epithelial cells from fresh human PCa cases …
BACKGROUND: Hormonal therapy targeting the androgen receptor inhibits prostate cancer (PCa), but the tumor eventually recurs as castr …
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.
Chen CC, Tran W, Song K, Sugimoto T, Obusan MB, Wang L, Sheu KM, Cheng D, Ta L, Varuzhanyan G, Huang A, Xu R, Zeng Y, Borujerdpur A, Bayley NA, Noguchi M, Mao Z, Morrissey C, Corey E, Nelson PS, Zhao Y, Huang J, Park JW, Witte ON, Graeber TG. Chen CC, et al. Cancer Cell. 2023 Dec 11;41(12):2066-2082.e9. doi: 10.1016/j.ccell.2023.10.009. Epub 2023 Nov 22. Cancer Cell. 2023. PMID: 37995683 Free article.
Trans-differentiation from an adenocarcinoma to a small cell neuroendocrine state is associated with therapy resistance in multiple cancer types. To gain insight into the underlying molecular events of the trans-differentiation, we perform a mul …
Trans-differentiation from an adenocarcinoma to a small cell neuroendocrine state is associated with therapy res …
Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.
Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, Huang J, Kurdistani SK, Graeber TG, Witte ON. Park JW, et al. Science. 2018 Oct 5;362(6410):91-95. doi: 10.1126/science.aat5749. Science. 2018. PMID: 30287662 Free PMC article.
The use of potent therapies inhibiting critical oncogenic pathways active in epithelial cancers has led to multiple resistance mechanisms, including the development of highly aggressive, small cell neuroendocrine carcinoma (SCNC). SCNC patients have a dismal prog …
The use of potent therapies inhibiting critical oncogenic pathways active in epithelial cancers has led to multiple resistance mechanisms, i …
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, Choueiri TK, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ, Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM. Zhao SG, et al. J Clin Invest. 2022 Nov 1;132(21):e161858. doi: 10.1172/JCI161858. J Clin Invest. 2022. PMID: 36317634 Free PMC article.
BackgroundNeuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.MethodsWe performed analytical validation of a Circulating Tumor Cell (CTC) multiplex RNA …
BackgroundNeuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and mana …
Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.
Zamora I, Freeman MR, Encío IJ, Rotinen M. Zamora I, et al. Int J Mol Sci. 2023 Sep 5;24(18):13673. doi: 10.3390/ijms241813673. Int J Mol Sci. 2023. PMID: 37761978 Free PMC article. Review.
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges through a transdifferentiation process from prostate adenocarcinoma and evades conventional therapies. ...A diverse array of targe …
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges thro …
Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S, Inoue T, Ogawa O, Gleave ME. Akamatsu S, et al. Int J Urol. 2018 Apr;25(4):345-351. doi: 10.1111/iju.13526. Epub 2018 Feb 3. Int J Urol. 2018. PMID: 29396873 Review.
Treatment-related neuroendocrine prostate cancer transdifferentiates from adenocarcinoma as an adaptive response to androgen receptor pathway inhibition. ...Typically, treatment-related neuroendocrine prostate cancer is characterized by either l …
Treatment-related neuroendocrine prostate cancer transdifferentiates from adenocarcinoma as an adaptive response to and …
EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.
Soundararajan R, Paranjape AN, Maity S, Aparicio A, Mani SA. Soundararajan R, et al. Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):229-238. doi: 10.1016/j.bbcan.2018.06.006. Epub 2018 Jul 5. Biochim Biophys Acta Rev Cancer. 2018. PMID: 29981816 Free PMC article. Review.
Neuroendocrine/Aggressive Variant Prostate Cancers are lethal variants of the disease, with an aggressive clinical course and very short responses to conventional therapy. ...In this review, we examine the contributions of EMT-induced cellular-plasticity and …
Neuroendocrine/Aggressive Variant Prostate Cancers are lethal variants of the disease, with an aggressive clinical course …
The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.
Ji Y, Zhang W, Shen K, Su R, Liu X, Ma Z, Liu B, Hu C, Xue Y, Xin Z, Yang Y, Li A, Jiang Z, Jing N, Zhu HH, Dong L, Zhu Y, Dong B, Pan J, Wang Q, Xue W. Ji Y, et al. Nat Commun. 2023 Nov 28;14(1):7794. doi: 10.1038/s41467-023-43676-3. Nat Commun. 2023. PMID: 38016952 Free PMC article.
Neuroendocrine prostate cancer is a rapidly progressive and lethal disease characterized by early visceral metastasis, poor prognosis, and limited treatment options. ...Here, we demonstrate that the RNA-binding protein ELAVL3 is specifically upregulated in …
Neuroendocrine prostate cancer is a rapidly progressive and lethal disease characterized by early visceral metastasis, poor …
Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. de Kouchkovsky I, et al. Prostate. 2024 Apr;84(5):426-440. doi: 10.1002/pros.24664. Epub 2024 Jan 3. Prostate. 2024. PMID: 38173302 Review.
BACKGROUND: Although most patients with prostate cancer (PC) respond to initial androgen deprivation therapy (ADT), castration-resistant disease invariably develops. Progression to treatment-emergent neuroendocrine PC (t-NEPC) represents a unique mechanism of resist …
BACKGROUND: Although most patients with prostate cancer (PC) respond to initial androgen deprivation therapy (ADT), castration-resist …
214 results